Alexander C.J. Van Akkooi, MD, PhD, FRACS, discusses how discrepancies in local and central pathologic review can expose patients to potential toxicities associated with overtreatment for metastatic melanoma.
Alexander van Akkooi, MD, PhD, FRACS
Advertisement
Articles by Alexander van Akkooi, MD, PhD, FRACS
Alexander C. Van Akkooi, MD, PhD, FRACS, discusses the prognostic value of minimal sentinel node tumor burden in melanoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5